Cargando…

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine

Although treatment options for melanoma patients have expanded in recent years with the approval of immunotherapy and targeted therapy, there is still an unmet need for new treatment options for patients that are ineligible for, or resistant to these therapies. BH3 mimetics, drugs that mimic the act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dart, Chiara R., Mukherjee, Nabanita, Amato, Carol M., Goulding, Anabel, MacBeth, Morgan, Van Gulick, Robert, Couts, Kasey L., Lambert, James R., Norris, David A., Robinson, William A., Shellman, Yiqun G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399604/ https://www.ncbi.nlm.nih.gov/pubmed/34451846 http://dx.doi.org/10.3390/ph14080749

Ejemplares similares

MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
por: Mukherjee, Nabanita, et al.
Publicado: (2020)

Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma
por: Mukherjee, Nabanita, et al.
Publicado: (2020)

BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
por: Mukherjee, Nabanita, et al.
Publicado: (2018)

Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells
por: Mukherjee, Nabanita, et al.
Publicado: (2016)

Enrichment of Melanoma Stem-Like Cells via Sphere Assays
por: Mukherjee, Nabanita, et al.
Publicado: (2021)

Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells
por: Mukherjee, Nabanita, et al.
Publicado: (2015)

Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells
por: Mukherjee, Nabanita, et al.
Publicado: (2014)

Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments
por: Mukherjee, Nabanita, et al.
Publicado: (2016)

Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunity
por: Turner, Jacqueline A., et al.
Publicado: (2023)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
por: Hollenbach, Paul W., et al.
Publicado: (2010)

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma
por: Hintzsche, Jennifer D., et al.
Publicado: (2017)

P582: AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS
por: Pan, Hong, et al.
Publicado: (2023)

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
por: Garcia-Manero, G, et al.
Publicado: (2016)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

A simple technique for quantifying apoptosis in 96-well plates
por: Ribble, Deborah, et al.
Publicado: (2005)

Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma
por: Akturk, Halis Kaan, et al.
Publicado: (2022)

A Simple Protocol for Using a LDH-Based Cytotoxicity Assay to Assess the Effects of Death and Growth Inhibition at the Same Time
por: Smith, Shilo M., et al.
Publicado: (2011)

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens
por: Jensen, Christopher E., et al.
Publicado: (2022)

PB1852: AZACITIDINE COMBINED WITH HAG REGIMEN FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA:PRIMARY ANALYSIS OF A RETROSPECTIVE COHORT
por: Zheng, W., et al.
Publicado: (2022)

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
por: Döhner, Hartmut, et al.
Publicado: (2018)

BRAF Modulates Lipid Use and Accumulation
por: Turner, Jacqueline A., et al.
Publicado: (2022)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
por: Bhatt, Anjali, et al.
Publicado: (2022)

CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1
por: Deng, Hui, et al.
Publicado: (2013)

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
por: Seymour, John F., et al.
Publicado: (2017)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

Azacitidine: No therapeutic response: case report
Publicado: (2020)

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
por: Schlenk, R. F., et al.
Publicado: (2019)

Circulating CD8(+) mucosal‐associated invariant T cells correlate with improved treatment responses and overall survival in anti‐PD‐1‐treated melanoma patients
por: Vorwald, Victoria M, et al.
Publicado: (2022)

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014)

Outcomes Following ACL and Grade III MCL Injuries: Is there a Role for MCL Repair?
por: Westermann, Robert W., et al.
Publicado: (2017)

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Azacitidine in outpatient treatment – single center experience
por: Rybka, Justyna, et al.
Publicado: (2016)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
por: Fenaux, P, et al.
Publicado: (2008)

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports
por: Wang, Bin-Ru, et al.
Publicado: (2021)

Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia
por: Feng, Yimei, et al.
Publicado: (2023)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_93ereomsr2ju94u73mjskr66a2